Super ‘bowel’ score: Furiex riding high after phase III victory with eluxadoline
Furiex Pharmaceuticals Inc.’s Phase III win with lead compound eluxadoline in diarrhea-predominant irritable bowel syndrome (IBS-D) turned investors’ eyes to next moves, including a potential partner for the locally acting mu opioid receptor agonist and delta opioid receptor antagonist or a possible buyout.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST